In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...
15h
Clinical Trials Arena on MSNPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialThe trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results